2 recruiting, 1 active not recruiting, 1 unknown. 2 Phase 1, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Unknown 1 |
| Phase 4 | 2 | Recruiting 2 |
Follow Staphylococcus Aureus Bloodstream Infection: new trials by email Literature Review of Staphylococcus Aureus Bloodstream Infection trials Research Report on Staphylococcus Aureus Bloodstream Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adults AZD7760, Placebo - Staphylococcus Aureus Bloodstream Infection | Phase 1 | Active not recruiting | AstraZeneca | 18 | 2026-06-29 | 2026-10-06 |
| Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia Dabigatran, Apixaban, edoxaban - Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia | Phase 4 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 300 | 2026-01-15 | 2026-09-24 |
| Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia Clopidogrel, Aspirin - Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia | Phase 4 | Recruiting | Todd C. Lee MD MPH FIDSA | 300 | 2026-01-15 | 2026-09-24 |
| A Phase I Study of XJ101 in Chinese Healthy Subjects XJ101 for Injection, Placebo - Staphylococcus Aureus Bloodstream Infection | Phase 1 | Unknown | Starmab biologics（Shanghai）Co,.ltd | 38 | 2023-08-15 | 2024-06-14 |
Aspirin (1) · Clopidogrel (1) · Dabigatran (1) · Injections (1) · Rivaroxaban (1) · apixaban (1) · edoxaban (1)
AstraZeneca (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Starmab biologics（Shanghai）Co,.ltd (1) · Todd C. Lee MD MPH FIDSA (1)
Canada (2) · China (1) · Japan (1)
Emily G McDonald, MD MSC (1) · Emily G McDonald, MD MSc (1) · Todd C Lee, MD MPH FIDSA (1)
2025 (2)